ArticleJournal of translational medicine2026
Clinical and immunological significance of tertiary lymphoid structure maturation heterogeneity in brain metastases of lung adenocarcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates that arise within the tumor microenvironment and orchestrate local immune responses. While TLSs have been associated with favorable prognosis and enhanced immunotherapy efficacy in various solid tumors, their heterogeneity, spatial organization, and functional significance in brain metastases from lung adenocarcinoma (LUAD-BrM) remain poorly understood.
methodsWe retrospectively analyzed 283 surgically resected LUAD-BrM specimens. TLSs were identified on H&E and classified by serial IHC into immature (E-TLS) and mature subtypes (PFL-TLS/SFL-TLS). Multiplex IHC incorporating follicular network and vascular-stromal markers (including CD35, CD31, and COL1A1) was used for spatial validation. Survival was assessed using Kaplan-Meier and multivariable Cox models.
resultsPatients were stratified into TLS-negative (n = 200), immature TLS (n = 43), and mature TLS (n = 40) groups. Spatial mapping revealed that mature TLS subtypes were more frequently intratumoral, whereas early TLSs were relatively enriched at peritumoral regions. Clinically, mature TLSs were associated with significantly prolonged survival (median PFS: 14.8 vs. 9.9 vs. 6.3 months; median OS: not reached vs. 13.3 vs. 10.2 months; all P < 0.001) and remained an independent favorable prognostic factor. Multiplex IHC profiling demonstrated that mature TLSs were associated with an immune-activated niche characterized by higher CD8⁺ infiltration, reduced PD-1⁺CD8⁺ exhaustion-like features, and decreased immunosuppressive macrophage and PD-L1-associated signals. Single-slide spatial mIHC further validated mature TLS architecture, demonstrating stronger B/T compartmentalization, prominent follicular network features, and enriched vascular-stromal contextualization compared with immature TLSs.
conclusionTLSs in LUAD brain metastases exhibit marked heterogeneity in maturation and spatial distribution, which stratifies immune contexture and patient outcomes. Mature, intratumoral TLSs define an immune-permissive niche and are associated with significantly improved survival. Collectively, these results highlight TLS maturity as a clinically actionable feature for risk stratification and may inform future TLS-guided precision immunotherapy approaches in LUAD-BrM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.